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ABSTRACT
Background. We conducted a phase I clinical trial to
evaluate the sensitivity, specificity, and safety of cytore-
ductive surgery (CRS) under aminolevulinic acid-mediated
photodynamic diagnosis (ALA-PDD) plus hyperthermic
intraperitoneal chemotherapy (HIPEC) on 20 patients with
peritoneal carcinomatosis (PC) from ovarian cancer and
primary peritoneal carcinoma (PPC).
Patients and Methods. Patients took 5-aminolevulinic
acid (5-ALA) at a dose of 20 mg/kg orally with 50 mL of
water 2 h before surgery. During surgery, the abdominal
cavity was observed under blue light (wavelength of
440 nm) before and after CRS plus HIPEC. Specimens
were excised and submitted for pathological examination
to evaluate the specificity of ALA-PDD. Postoperative
course was closely monitored and detailed information was
recorded.
Results. CRS under ALA-PDD plus HIPEC was per-
formed 21 times in 20 patients with PC (16 ovarian cancer,
4 PPC) between June 2011 and October 2013. With the
exception of 1 (5 %) patient, strong red fluorescence was
detected in 19 patients with ovarian cancer, with a sensi-
tivity of 95 %. All specimens from red fluorescent lesions
were invaded by cancer cells, with a specificity of 100 %.
No severe adverse events occurred during the perioperative
period, with the exception of some abnormal laboratory
results and mild complications. All patients were alive until
the last follow-up.
Conclusion. ALA-PDD provided a high sensitivity and
specificity in detecting peritoneal metastasis in patients
with PC from ovarian serous carcinoma and PPC. CRS
under ALA-PDD plus HIPEC was a feasible and safe
treatment option for patients with PC from ovarian cancer
and PPC.
Ovarian cancer is the eighth most frequent cancer in
women, and the main cause of death from gynecological
cancers worldwide.1 In Japan, there are about 10,000 new
cases and 4,600 deaths annually.2 The majority of patients
were in the advanced stage at first diagnosis, with a 5-year
survival rate of 15–37 %.3 Primary peritoneal carcinoma
(PPC) is a rare extra-ovary serous malignancy originating
from the peritoneum, which has similar histological and
clinical characteristics as advanced ovarian cancer.4
Advanced ovarian cancer and PPC progress principally
within the abdominal cavity with ascites, lymph node
metastasis, and peritoneal dissemination. A new strategy
with a combination of cytoreductive surgery (CRS) and
hyperthermic intraperitoneal chemotherapy (HIPEC) has
been widely demonstrated as being effective for treating
patients with peritoneal carcinomatosis (PC).5–9 Selected
patients with advanced ovarian cancer and PPC could also
benefit from optimal CRS and HIPEC.4,10
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Aminolevulinic acid-mediated photodynamic diagnosis
(ALA-PDD) is a new and effective method of detecting
dysplasia and early-stage cancer lesion. It works by detect-
ing a specific wavelength light generated from cancer cells
under irradiation with an exciting light after administration
of 5-aminolevulinic acid (5-ALA). ALA is a prodrug of
heme biosynthesis. It can be converted to the photosensi-
tizing agent protoporphyrin IX (PpIX). After administration
of 5-ALA, PpIX accumulates in cancer tissue in a tumor-
specific form, which contributes to easy identification of
cancer tissue through irradiation with an exciting light.
Meanwhile, cancer cells also get killed by reactive oxygen
species, a cytotoxic production produced by PpIX under
irradiation of exciting light. This strategy is named ALA-
mediated photodynamic therapy (ALA-PDT).11 Due to their
tumor-specific characteristics and less invasion, ALA-PDD
and ALA-PDT have been widely applied in detecting and
treating a variety of dysplasias and cancers such as Barrett’s
esophagus, ulcerative colitis, skin cancer, brain cancer,
gastric cancer, bladder cancer, and ovarian cancer.11–13
According to the study of Lo¨ning et al.14, ALA-PDD
was able to provide high sensitivity for the detection of
peritoneal disseminated tumor for laparoscopic diagnosis
in patients with ovarian cancer after intraperitoneal
administration of 5-ALA. This might be helpful for treating
patients with PC from ovarian cancer and PPC by CRS plus
HIPEC. Therefore, we performed a phase I trial to evaluate
the feasibility and safety of CRS under ALA-PDD plus
HIPEC in patients with PC from ovarian cancer and PPC.
PATIENTS AND METHODS
Patients
From June 2011 to October 2013, a phase I clinical trial
for treating patients with PC from ovarian cancer and PPC
by CRS under ALA-PDD plus HIPEC was conducted in
the Peritoneal Dissemination Center of Kishiwada Toku-
shukai Hospital, Osaka, Japan. The protocol of this study
was approved by the Ethics Committee of Kishiwada
Tokushukai Hospital (No-24-05), and all patients provided
written informed consent to participate in this study. A
total of 20 patients were enrolled in the study—16 patients
with ovarian cancer, and 4 patients with PPC. The major
clinicopathological characteristics of the patients are listed
in Table 1.
Cytoreductive Surgery Under ALA-PPD Plus
Hyperthermic Intraperitoneal Chemotherapy
All patients were treated with the intention of achiev-
ing complete CRS. Meticulous preoperative assessment
was performed. Patients were administered 5-ALA
(Cosmo Bio Co., Ltd, Tokyo, Japan) at a dose of 20 mg/
kg orally with 50 mL of water 2 h before surgery, which
was performed under general anesthesia and hemody-
namic monitoring. Once the abdominal wall was open,
20 mL of ascites was sent for cytological examination.
Meanwhile, detailed evaluation of the peritoneal cancer
index (PCI) was conducted according to the principle of
Sugarbaker.15 After evaluation, four biopsy specimens
were excised, two of which were tumor tissue and two
were normal tissue. Tumor tissue and normal tissue were
discriminated under white light. Next, all lights in the
surgery room were turned off. The abdominal cavity was
observed under blue light (wavelength of 440 nm). Tumor
tissue would emit red fluorescence under irradiation of
blue light. Another four biopsy specimens were then
taken—two specimens from red fluorescent lesions and
two from non-fluorescent areas. All biopsy specimens
were submitted for pathological examination. Optimal
CRS was then carried out according to the peritonectomy
procedure described by Sugarbaker.15
HIPEC was performed after optimal CRS with an open
technique for 40 min, with 4 L of heated saline containing
40 mg of docetaxel (Sanofi K.K. Co., Ltd, Tokyo, Japan)
and 100 mg of cisplatin (Nippon Kayaku Co., Ltd, Tokyo,
Japan). The temperature of the solution was maintained at
42.9–43.5 C during the entire procedure. After HIPEC,
the abdominal cavity was again observed under blue light
to check if the tumors had been totally removed. Drainage
tubes were placed at appropriate sites and chest drainage
tubes were also placed if subphrenic peritonectomy was
performed. The wound was closed, and the patient was sent
to the recovery room.
The extent of CRS was determined by completeness of
cytoreduction (CC), according to the criteria described by
Sugarbaker.15 CC-0 indicates no residual tumor; CC-1
TABLE 1 Clinicopathological characteristics of 20 patients with
peritoneal carcinomatosis
Characteristics Value
Demographic parameters
Age (years, range [median]) 44–75 (63)
Sex (female/male) 19/1
Clinicopathological parameters (n)
Ovarian cancer 16
Primary peritoneal carcinoma 4
Histological diagnosis
Serous adenocarcinoma 16
Serous papillary carcinoma 3
Serous papillary adenocarcinoma 1
Peritoneal carcinomatosis index (range) 2–33
Completeness of cytoreduction (range) 0–3
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represents \2.5 mm of residual tumor; CC-2 indicates
residual tumor between 2.5 mm and 2.5 cm; and CC-3
indicates [2.5 cm of residual tumor.
Postoperative Monitoring and Follow-Up
All patients were closely monitored for the following
parameters: vital signs, drainage, flatus passage, and any
discharge. Complete peripheral blood tests and blood
chemistry were examined on the first, fourth, and seventh
postoperative day. Pulmonary cardiovascular functions
were monitored. Other postoperative care information was
also detailed and recorded, including condition of the
incision, time on liquid food, time to suture removal, time
to remove drainage tube, and time to be discharged. Three
weeks after being discharged, patients received intraperi-
toneal, intravenous, or oral chemotherapy. Adverse events
that occurred during the perioperative period were graded
according to the NCI-CTC Version 4.
All patients were routinely followed up either by out-
patient clinic or telephone. The last time of follow-up was
1 February 2014.
Statistical Analysis
Data were obtained from a database of clinical records,
surgical reports, laboratory and pathology reports, and
follow-up records. The numerical data were directly
recorded, and the category data were recorded into differ-
ent categories. The survival time was calculated from the
date of first CRS under ALA-PDD plus HIPEC to the date
of patient death. Data were analyzed by SPSS software,
version 17.0 (SPSS, Inc., Chicago, IL, USA), with a p
value \0.05 considered to be statistically significant.
RESULTS
CRS under ALA-PDD plus HIPEC was performed 21
times in 20 patients. One patient with ovarian cancer
underwent another CRS under ALA-PDD plus HIPEC for a
second look 18 months after the first operation. For all 21
surgeries, all patients underwent optimal CRS. From the
results of cytological examination, there were 12 episodes
where cancer cells were found to be positive. The PCI of
patients was 2–33 (median 11). Complete cytoreduction of
CC-0/CC-1 was achieved 14 times. Incomplete cytore-
duction of CC-2/CC-3 was performed seven times. Time of
surgery ranged from approximately 1.5–6.0 h (median
4.0 h). The volume of blood loss during surgery was 300–
2,400 mL (mean 950 mL). Mean blood requirement was
6.4 (range 0–10) units of packed red cells and for fresh
frozen plasma was 8.6 (range 2–10) units.
Postoperative Course
Postoperative vital signs of all patients were almost in
the normal range and stable within the first postoperative
week, except one patient who experienced a heart rate of
[100 times per min after surgery and two patients who
experienced fever with a temperature of 38.0 C. No
hypertension or hypotension occurred during the periop-
erative course. Laboratory results of the peripheral blood
test, liver function, renal function, and C-reactive protein
(CRP) on the first and seventh postoperative day, and on
TABLE 2 Laboratory results of postoperative course
Parameter Range (median) Normal value
Day 1 Day 7 Day of discharge
Hg (g/dL) 8.0–12.6 (10.0) 10.2–11.3 (11.0) 10.6–12.6 (11.6) 12.0–16.0
RBC (104/lL) 246–402 (350) 327–368 (347) 342–423 (370) 360–480
WBC (102/lL) 55–161 (122.5) 70–110 (92) 51–81 (60) 40–85
NEU % 64.5–88.0 (83.8) 72.0–80.6 (76.5) 43.2–75.0 (65) 40–70
Platelet (104/lL) 9.9–41.9 (13.5) 23.9–35.3 (27.5) 15.0–42.0 (26.0) 13.0–36.0
AST 32–129 (80) 20–35 (29) 17–37 (24) 13–37
ALT 18–127 (101) 8–52 (13) 8–45 (25.5) 8–45
TB 0.53–2.04 (1.14) 0.49–1.22 (0.84) 0.38–1.25 (0.89) 0.30–1.30
ALB 2.4–3.1 (2.7) 3.2–3.9 (3.6) 3.4–4.8 (4.1) 4.1–5.2
BUN 6.6–18.1 (10.3) 6.5–17.9 (11.9) 6.8–18.3 (13.0) 7.8–18.9
Creatine (U/L) 0.45–1.32 (0.63) 0.48–0.93 (0.55) 0.56–0.81 (0.67) 0.45–0.82
CRP 0.4–10.2 (6.24) 0.86–9.30 (4.80) 0.10–2.02 (1.20) 0.00–0.30
Hg hemoglobin, RBC red blood cell, WBC white blood cell, NEU neutrophilic granulocyte, AST aspartate aminotransferase, ALT alanine
aminotransferase, TB total bilirubin, ALB albumin, BUN blood urea nitrogen, CRP C-reactive protein
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the day of discharge, are listed in Table 2. On the first
postoperative day, the most common abnormalities were
hypoproteinemia, high white blood cell count, and alter-
nation of liver function. One week later, CRP remained
abnormal in the majority of patients, but decreased con-
tinually to reach normal levels. On the day of discharge,
almost all data were in the normal range. The incisions
recovered well without any infection. The time to suture
removal ranged from 7 to 13 days (median 10 days), time
on liquid food ranged from 3 to 12 days (median 5 days),
time to remove the drainage tube ranged from 3 to 7 days
(median 4 days), and time to be discharged ranged from 10
to 42 days (median 28 days).
Adverse Events and Follow-Up
No severe adverse event occurred in the perioperative
period; however, one patient lost her appetite for 12 days
after the operation, one patient experienced diarrhea
for 3 days, and two patients were with pleural effusion
after subphrenic peritonectomy. All these symptoms
disappeared after taking timely treatment. By the last
follow-up on 1 February 2014, all 20 patients were alive.
Detailed information for each patient is summarized in
Table 3.
Sensitivity of ALA-PDD During Operation
During 20 episodes of initial CRS under ALA-PDD
plus HIPEC, peritoneal metastases emitted red fluores-
cence under irradiation of blue light in 19 patients, with a
sensitivity of 95 % (Fig. 1), while peritoneal disseminated
gross tumor nodules seen with white light in one (5 %)
patient with ovarian cancer did not emit red fluorescence
under irradiation of blue light. The smallest tumor that we
detected was 0.5 mm in diameter. For the second surgery
of the patient with ovarian cancer, no red fluorescence
was detected, and no malignancy was found from the
results of frozen and final pathological examination.
Moreover, residual tumor in all patients undergoing
incomplete CRS emitted red fluorescence after HIPEC
(Fig. 2).
TABLE 3 Clinical and pathological features of 20 patients undergoing 21 episodes of CRS under ALA-PDD plus HIPEC
Patient no. Age (years) Sex Diagnosis Histology Fluorescence
emission
PCI CC Survival
(months)
1 64 F OC Serous adenocarcinoma Yes 30 3 4
2 60 F OC Serous adenocarcinoma Yes 27 2 12
3 63 F OC Serous adenocarcinoma Yes 5 0 22
4 44 F OC Serous adenocarcinoma Yes 11 0 24
5 48 F OC Serous adenocarcinoma Yes 3 0 18
6 65 F OC Serous adenocarcinoma Yes 12 1 8
7 66 F OC Serous adenocarcinoma Yes 6 0 10
8 66 F OC Serous adenocarcinoma Yes 12 3 6
9 67 F OC Serous adenocarcinoma Yes 18 1 12
10 65 F OC Serous adenocarcinoma Yes 25 2 10
11 64 F OC Serous adenocarcinoma Yes 2 0 20
12 75 F OC Serous adenocarcinoma Yes 15 0 16
13 49 F OC Serous adenocarcinoma Yes 4 0 15
14 60 F OC Serous adenocarcinoma No 4 0 12
15 68 F OC Serous adenocarcinoma Yes 6 0 16
16 45 F OC Serous adenocarcinoma No 35 2 27
16* 47 F OC No malignancy Yes 2 0 27
17 59 F PPC Serous papillary carcinoma Yes 8 0 26
18 61 F PPC Serous papillary carcinoma Yes 24 2 17
19 63 M PPC Serous papillary carcinoma Yes 30 3 24
20 61 F PPC Serous papillary adenocarcinoma Yes 2 0 32
CRS cytoreductive surgery, ALA-PDD aminolevulinic acid-mediated photodynamic diagnosis, HIPEC hyperthermic intraperitoneal chemo-
therapy, F female, M male, OC ovarian cancer, PPC primary peritoneal carcinoma, PCI peritoneal cancer index, CC completeness of
cytoreduction
16* the same patients as No 16, who underwent a second CRS under ALA-PDD plus HIPEC
CRS Under ALA-PDD Plus HIPEC 4259
Pathological Examination Results of Biopsy Specimens
For 21 surgeries, a total of 158 biopsy specimens were
excised and examined. In the second surgery of CRS under
ALA-PDD for the patient with ovarian cancer, no specimen
was excised since no red fluorescence was detected, and
frozen pathological examination showed no malignancy.
All 40 tumor specimens obtained under white light and 38
specimens from red fluorescent lesions were positive for
cancer cells, with a specificity of 100 %. Among 40 normal
specimens excised under white light, five specimens were
tumors. For the other 40 specimens from the non-fluores-
cent area, three specimens were tumors, with a false
negative rate of 7.5 % (Table 4).
DISCUSSION
To our knowledge, this is the first study suggesting
that ALA-PDD may be effective in detecting peritoneal
metastasis originating from PPC, as well as from ovarian
FIG. 1 Peritoneal disseminated tumors from ovarian cancer and
primary peritoneal carcinoma emitted strong red fluorescence under
irradiation of blue light. Arrows indicate peritoneal disseminated
tumor emitting strong red fluorescence. a Peritoneal disseminated
tumors from ovarian cancer; b peritoneal disseminated tumors from
primary peritoneal carcinoma
FIG. 2 Recheck residual tumors under irradiation of blue light after
cytoreductive surgery and hyperthermic intraperitoneal chemother-
apy. a No red fluorescence was detected under irradiation of blue light
after complete cytoreduction; b residual tumor on bowel mesentery
still emitted weak red fluorescence after cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy
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cancer. A series of experimental and clinical studies
demonstrated that ALA-PDD was able to detect perito-
neal metastases from different cancers.14,16–18 Lo¨ning
et al.14 reported the first study evaluating the use of
ALA-PDD in finding peritoneal metastasis of epithelian
ovarian carcinoma. In their study, peritoneal metastases
in 12 cases emitted strong red fluorescence among 13
patients after intraperitoneal application of 5-ALA. In our
study, peritoneal metastases in 15 patients with PC from
ovarian cancer emitted strong red fluorescence after oral
application of 5-ALA. With a combination of the results
of Lo¨ning et al.14. and our results, peritoneal metastases
in 27 cases emitted strong red fluorescence among 29
patients treated by ALA-PDD, with a high sensitivity of
93.1 %. This may provide more convincing evidence to
support the fact that ALA-PDD could provide a high
sensitivity of detecting peritoneal metastasis in patients
with ovarian cancer. Moreover, in all four cases of PPC,
peritoneal metastases also emitted strong red fluores-
cence. Although four cases were not enough, they still
provided evidence that ALA-PDD might be effective in
detecting peritoneal metastasis in patients with PCC. In
addition, we noticed that all patients in this study had
serous adenocarcinoma or serous papillary carcinoma.
These cancers share similar histological and clinical
features. Therefore, we infer that ALA-PDD might also
be sensitive in detecting peritoneal metastasis from other
serous carcinoma.
This is also the first study evaluating the safety of CRS
plus HIPEC with the application of ALA-PDD. It suggests
that CRS under ALA-PDD plus HIPEC would be a safe
strategy for treating patients with PC. Usually, ALA-PDD
is a safe procedure; however, some adverse events have
been reported. The main potential side effects of oral
administration of 5-ALA included hypotension, alternation
of liver function, urinary frequency, nausea, and vomit-
ing.19,20 In addition, CRS plus HIPEC has a high risk of
postoperative complications. As a result, it was necessary
to evaluate safety first. In the present study, no severe
adverse event occurred, with the exception of two patients
with pleural effusion, one patient who lost her appetite, one
patient who experienced diarrhea, and some abnormal
results in laboratory data. It was difficult to prove a direct
relationship between such complications and ALA-PDD.
However, all these abnormalities disappeared after timely
treatment and patients underwent uneventful recovery
courses. This good result might be attributed to a well-
experienced team with good team work and a safe dose of
20 mg/kg of 5-ALA, as recommended by Chung and
Eljame.19
For patients with PC from ovarian cancer and PPC
undergoing CRS and HIPEC, complete cytoreduction was
an independent factor predicting better survival and prog-
nosis.4,21 Therefore, tumors should be removed as far as
possible. ALA-PDD was helpful in achieving this goal; in
addition to high sensitivity, it could detect a microscopic
tumor with high specificity. The smallest tumors detected
by ALA-PDD had a diameter of 0.5 mm, in the present
study. In another report, smaller tumors of \0.5 mm
diameter were also detected.14 Thus, microscopic tumors
that were usually ignored might be removed with the help
of ALA-PDD. Moreover, Takahashi et al.22, found that
administration of ALA markedly enhanced the antitumor
effect of hyperthermotherapy on an animal mode; it might
also enhance the effect of HIPEC. For this reason, we
believe that ALA-PDD provided help not only on surgery,
but also on chemotherapy.
Several studies on treating patients with PC by PDT have
been performed; however, the results were not encouraging.
In the study of Hendren et al.23, 42 patients received PDT
under irradiation of laser after debulking surgery with a
residual tumor B5 mm in diameter, with a median survival
of 21 months. However, the study had some deficiencies:
(1) lack of control results for patients undergoing only
debulking surgery to prove the contribution of PDT and
adverse effects related to PDT; (2) Photofrin used in their
study could not produce enough cytotoxic effect to cancer
cells, and, in addition, Photofrin required a long clearance
time of 4–8 weeks after injection; and (3) exact efficacy of
debulking surgery with PDT in patients with a specific type
of cancer could not be told owing to ignoring different
effects of PDT on various cancers. Similar problems were
found in another similar study reported by Hahn et al.24
CRS plus HIPEC has been proven to have better efficacy
than debulking surgery. Moreover, 5-ALA used in our study
has been proven to be better than Photofrin in enhancing the
effect of ALA-PDD. We believe that patients with PC
originating from ovarian cancer and PPC would benefit
more from the new treatment of CRS under ALA-PDD plus
HIPEC.
CONCLUSIONS
CRS under ALA-PDD plus HIPEC is a feasible and
relative safe treatment option in selected patients with PC
TABLE 4 Results of biopsies under white light and under irradiation
of blue light
Tumor No tumor p value
White light
Tumor 40 0 0.000
Normal tissue 5 35
Blue light
Red fluorescence 38 0 0.000
No red fluorescence 3 37
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originating from ovarian cancer and PPC. With the results
of this study, a higher-level clinical trial needs to be per-
formed to provide more supportive evidence.
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